Gyala Therapeutics

Gyala Therapeutics is developing next-generation immunotherapies for the treatment of hematological cancers with unmet needs. Its lead program, GYA01, is a first-in-class CAR-T therapy targeting CD84, a protein overexpressed in AML, T-ALL, and other blood cancers.